Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03906617 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 12, 2021 (before its estimated April 10, 2022 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Apr 10, 2020 to Apr 10, 2022 Completion date: Jun 10, 2020 to Jun 10, 2022v3 Show 1 more changeShow less
    • Completion date: Jun 10, 2020 to Jun 10, 2022
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will assess analgesia after robotic lung surgery. Subjects will be randomized to receive wound infiltration and intercostal nerve block with either liposomal bupivacaine or bupivacaine/epinephrine + dexamethasone. Liposomal bupivacaine is a newer local anesthetic product and has not been compared to a combination of bupivacaine/epinephrine + dexamethasone in the context of pain control after robotic lung surgery.
Trial Details
NCT Number NCT03906617
Lead Sponsor The Cooper Health System
Conditions Robotic Lung Surgery
Enrollment 34 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov